Johnson & Johnson | 10-K: FY2025 Annual Report

Johnson & Johnson delivered strong financial results in fiscal 2025, with worldwide sales increasing 6% to $94.2 billion, driven by 8.4% operational growth partially offset by a 3.1% negative price impact. The Innovative Medicine segment grew 6% to $60.4 billion while MedTech rose 6.1% to $33.8 billion. Net earnings surged 90% to $26.8 billion, with earnings per share of $11.03.The company's performance was highlighted by robust growth in key franchises, with Oncology sales up 22.1% to $25.4 billion led by DARZALEX and CARVYKTI, while TREMFYA grew 40.5% to $5.2 billion. However, STELARA sales declined 41.3% to $6.1 billion due to biosimilar competition. The MedTech segment saw strong growth in Cardiovascular, up 15.8% to $8.9 billion.Looking ahead, J&J announced plans to separate its Orthopaedics business within 18-24 months. The company maintained its innovation focus with R&D investment of $14.7 billion and new products launched within the past five years accounting for approximately 25% of sales. The Board approved a 4.7% dividend increase, marking the 63rd consecutive annual increase.

Johnson & Johnson delivered strong financial results in fiscal 2025, with worldwide sales increasing 6% to $94.2 billion, driven by 8.4% operational growth partially offset by a 3.1% negative price impact. The Innovative Medicine segment grew 6% to $60.4 billion while MedTech rose 6.1% to $33.8 billion. Net earnings surged 90% to $26.8 billion, with earnings per share of $11.03.The company's performance was highlighted by robust growth in key franchises, with Oncology sales up 22.1% to $25.4 billion led by DARZALEX and CARVYKTI, while TREMFYA grew 40.5% to $5.2 billion. However, STELARA sales declined 41.3% to $6.1 billion due to biosimilar competition. The MedTech segment saw strong growth in Cardiovascular, up 15.8% to $8.9 billion.Looking ahead, J&J announced plans to separate its Orthopaedics business within 18-24 months. The company maintained its innovation focus with R&D investment of $14.7 billion and new products launched within the past five years accounting for approximately 25% of sales. The Board approved a 4.7% dividend increase, marking the 63rd consecutive annual increase.